DiaMedica Therapeutics
Equisolve Logo
About Equisolve
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious vascular diseases, including acute ischemic stroke and preeclampsia. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1 intended to restore normal KLK1 protein levels and improve blood flow in patients with ischemic conditions. DiaMedica aims to address significant unmet medical needs and improve patient outcomes through novel approaches to vascular health.
Year founded
2000
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
